Genomic-Driven Precision Oncology With Next Generation Sequencing Testing
Comprehensive genomic testing with next-generation sequencing (NGS) can inform clinicians with valuable insights into available genomic-based targeted treatments and immunotherapies for cancer patients. However, implementing an effective and well-organized clinical precision oncology program can be challenging due to ever-growing and ever-changing molecular testing and treatment standards. This presentation will describe key components of precision cancer medicine: NGS testing, Molecular-Tumor-Board, and a review of 2021 FDA-approved new oncologic drugs. The presentation will conclude with a case study in precision oncology with a lung cancer patient with brain metastasis.
Originally published on March 6, 2023
Jong Taek Kim, MD, MS
Assistant Professor of PathologyUniversity of Utah School of Medicine
Medical Director, Molecular Oncology
ARUP Laboratories
Credits: .75